These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 8695345)
21. [Topoisomerase inhibitors developing in Japan]. Furue H Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186 [TBL] [Abstract][Full Text] [Related]
22. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. de Jonge MJ; Sparreboom A; Verweij J Cancer Treat Rev; 1998 Jun; 24(3):205-20. PubMed ID: 9767735 [No Abstract] [Full Text] [Related]
24. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Mathijssen RH; Loos WJ; Verweij J; Sparreboom A Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913 [TBL] [Abstract][Full Text] [Related]
25. Schedule-dependent efficacy of camptothecins in models of human cancer. Houghton PJ; Stewart CF; Zamboni WC; Thompson J; Luo X; Danks MK; Houghton JA Ann N Y Acad Sci; 1996 Dec; 803():188-201. PubMed ID: 8993512 [No Abstract] [Full Text] [Related]
26. New directions for chemotherapy in non-small-cell lung cancer. Green MR Chest; 1993 Apr; 103(4 Suppl):370S-372S. PubMed ID: 8096453 [TBL] [Abstract][Full Text] [Related]
27. A review of the clinical experience with irinotecan (CPT-11). Horowitz RW; Wadler S; Wiernik PH Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612 [TBL] [Abstract][Full Text] [Related]
28. [A symphony for the camptothecins]. Lansiaux A; Bailly C Bull Cancer; 2003 Mar; 90(3):239-45. PubMed ID: 12801826 [TBL] [Abstract][Full Text] [Related]
29. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan]. Bonneterre J Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818 [TBL] [Abstract][Full Text] [Related]
30. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Murphy BA Expert Opin Pharmacother; 2005 Jan; 6(1):85-92. PubMed ID: 15709886 [TBL] [Abstract][Full Text] [Related]
31. Topoisomerase I inhibition: a new target or new missiles? Verweij J; Schellens JH Ann Oncol; 1995 Feb; 6(2):102-4. PubMed ID: 7786815 [No Abstract] [Full Text] [Related]
32. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Hartmann JT; Lipp HP Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321 [TBL] [Abstract][Full Text] [Related]
34. New options for the treatment of advanced ovarian cancer. Dunton CJ Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739 [TBL] [Abstract][Full Text] [Related]
35. The current status of camptothecin analogues as antitumor agents. Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738 [TBL] [Abstract][Full Text] [Related]
37. Preclinical and clinical development of camptothecins. Costin D; Potmesil M Adv Pharmacol; 1994; 29B():51-72. PubMed ID: 8996601 [No Abstract] [Full Text] [Related]
38. Novel camptothecin derivatives. Legarza K; Yang LX In Vivo; 2005; 19(1):283-92. PubMed ID: 15796188 [TBL] [Abstract][Full Text] [Related]
39. [Clinical activity spectrum of irinotecan]. Cottu PH; Extra JM; Lerebours F; Espie M; Marty M Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080 [TBL] [Abstract][Full Text] [Related]